Recent Headlines
NAD3® Supplement Study: Memphis Health Sciences College Discovers Key to Cellular Rejuvenation
In a groundbreaking development, the College of Health Sciences at the University of Memphis, spearheaded by leading researchers Janine Hellenbrand, Richard J. Bloomer, and Marie Van der Merwe, has revealed the remarkable effects of NAD3® supplementation on adult stem cell circulation in... - February 14, 2024 - High Performance Nutrition
Biopharmaceutical Sponsor Interaction with Clinical Site Networks Pulse Report
Sponsor Outsourcing Dollars May Shift to Clinical Site Networks, Transforming the CRO Relationship - February 13, 2024 - Life Science Strategy Group, LLC
Microvascular Therapeutics Welcomes Thom Tulip as Chief Business Officer
Microvascular Therapeutics Inc. (MVT), a clinical-stage biotech company at the forefront of developing the next generation of microbubbles unlocking the therapeutic potential of ultrasound, proudly announces the appointment of Dr Thom Tulip as their new Chief Business Officer. In this pivotal role, Dr Tulip will lead capital raises to propel MVT's cutting-edge technologies into the market. - February 10, 2024 - Microvascular Therapeutics, Inc.
Flow Circuits and Rapid Fluidics Ltd. Announce Partnership to Drive Microfluidic Innovation
Flow Circuits design platform and Rapid Fluidics 3D Print capabilities perfectly complement each other for rapid fluidic system development. Combined they empower researchers in diverse markets such as Pharmaceutical & Life Sciences Research, Point of Care Testing and Clinical Diagnostics, and Environment and Industrial Analytics. - February 05, 2024 - Rapid Fluidics Ltd
Accelerating Drug Discovery: Life Science and IT Leaders Explore the Power of Artificial Intelligence April 15-17 in Boston
AI to Take Center Stage at Bio-IT World Conference & Expo, the Hub for Pharmaceutical, Biotech and IT Collaboration - February 04, 2024 - Cambridge Healthtech Institute
Patient Experience and Satisfaction with Electronic Consent, Onboarding, and Diaries in Clinical Trials Report
New Market Research Shows Different Patient Preferences for Electronic Diaries - January 31, 2024 - Life Science Strategy Group, LLC
New Sustainable Lyophilization Technology Uses Supercritical CO2
The Thar group of companies have been using CO2 for extraction, purification, particle design and encapsulation for many years but recent developments point to a need for sustainable methods for drying APIs, intermediates, excipients and biologics at relatively low temperatures. 'Big Pharma' has depended on Thar for SFC tools in drug discovery but lyophilization will likely be used in manufacturing too. - January 28, 2024 - Thar Process
Huntington Study Group Announces 2024 Annual Meeting
The Huntington Study Group® (HSG), together with its wholly owned subsidiary, HSG Clinical Research, Inc., a world leader in conducting clinical trials for Huntington’s disease (HD), is pleased to announce that its annual meeting for 2024 is slated to take place from November 6-9 at the... - January 22, 2024 - Huntington Study Group
Johari Digital Healthcare Limited Hosts Successful Webinar on Design for Manufacturing (DFM) for Medical Devices
Johari Digital Healthcare hosted a successful webinar on "Building Cost-effective Medical Devices through Design for Manufacturing." The 60-minute event discussed challenges in balancing cost and product robustness, featuring real-world case studies. Speakers highlighted early DFM benefits, such as cost reduction and faster time-to-market. - January 22, 2024 - Johari Digital Healthcare Ltd.
Impact of the In Vitro Diagnostic Regulation on Clinical Trials in the EU and CRO Outsourcing Report
IVDR Delays Driving Trial Sponsors to Actively Seek Alternative Site and CRO Outsourcing Strategies - January 17, 2024 - Life Science Strategy Group, LLC
New Ultra-Thin, Compact Low-Height, Low-Frequency Vibration Isolation Platform Adapts to Space Constraints in Critical Micro- and Nano-Microscopy
At about 2-1/2 inches in height, while isolating vibrations as low as 1 hertz, the new completely-passive Negative-Stiffness tabletop vibration isolation platform – developed by Minus K Technology – provides the industry’s thinnest low-height, low-frequency isolator for Microscopy (SPM, SEM, AFM, etc.), Micro-Hardness and Nano-Indenter Testing, Laser/Optical Systems, Biology/Neuroscience Systems, Spacecraft Ground Testing, Analytical Balances, Audio Reproduction, Vacuum & Cleanroom applications. - January 10, 2024 - Minus K Technology Inc.
ALPCO Announces the Commercial Launch of Its FDA 510(K) Cleared Calprotectin Immunoturbidimetric Assay
American Laboratory Products Company, Ltd. ("ALPCO"), a global provider of specialty diagnostic solutions, proudly announces the commercial launch of its FDA 510(k) cleared Calprotectin Immunoturbidimetric Assay, enhancing its suite of Gastrointestinal (GI) diagnostic solutions. In July... - December 19, 2023 - ALPCO
Johari Digital Healthcare Ltd. Clinches Prestigious "Pharmaceutical & Healthcare MSME of the Year" Award at ET MSME Awards 2023
Johari Digital Healthcare Ltd. has clinched the esteemed "Pharmaceutical & Healthcare MSME of the Year" award at the ET MSME Awards 2023 in New Delhi. Celebrating the resilience of India's MSME sector, the event recognized Johari Digital Healthcare Ltd. for its exceptional contributions to healthcare, particularly in manufacturing and research & development. - December 18, 2023 - Johari Digital Healthcare Ltd.
Empowering Data Privacy: GENINVO Offers Anonymization as a Service
GENINVO, a leading provider of life science product and business solutions announced the offering of its on-demand service Anonymization as a Service. GENINVO a trailblazer in data privacy solutions, is excited to introduce its ground-breaking offering, Anonymization as a Service. With data... - December 14, 2023 - GenInvo, Inc.
Huntington Study Group and Roche Collaborate on GENERATION HD2 Study
The Huntington Study Group together with its wholly-owned clinical research organization, HSG Clinical Research, Inc. (HSGCR), is pleased to announce a collaboration with Roche-Genentech to optimize our collective experiences in Huntington’s disease (HD) clinical research. Together we are... - December 13, 2023 - Huntington Study Group
Breakthrough Study by Microvascular Therapeutics Reveals Fibrin-Targeted Phase Shift Microbubbles as Promising Solution for Microvascular Obstruction
Microvascular Therapeutics, a trailblazing healthcare research and development company, announces a groundbreaking study on the treatment of Microvascular Obstruction (MVO) through sonoreperfusion. The study, led by Dr. John J. Pacella and his team at the Center for Ultrasound Molecular Imaging and... - December 13, 2023 - Microvascular Therapeutics, Inc.
Microvascular Therapeutics Selected as a Participant in the 2023 H7 BioCapital Accelerator Program
Microvascular Therapeutics (MVT), a clinical stage biopharma pioneering the potential of ultrasound in diagnostics and theranostics, has been selected to join the prestigious H7 Healthcare Accelerator 2023 Cohort, powered by H7 BioCapital. The program is renowned for providing a dynamic platform... - December 13, 2023 - Microvascular Therapeutics, Inc.
Herb Llama Launches Plant-Based, Adaptogenic Superfood Supplements: a Revolution in Modern Holistic Wellness
Herb Llama, an American wellness company, has launched a new range of adaptogenic, plant-based superfood supplements targeting health-conscious adults. The company, driven by the motto "vitamins as nature intended," ensures its plant-based products align with modern holistic wellness. - November 30, 2023 - Herb Llama
Huntington Study Group® Holds 30th Annual Meeting
The Huntington Study Group® (HSG®), a world leader in conducting clinical trials and providing educational programming for Huntington’s disease (HD), recently held its 30th annual meeting, HSG 2023, November 2-4 in Phoenix, AZ. Hundreds of scientists, industry partners, HSG research... - November 21, 2023 - Huntington Study Group
Performance Inspired Nutrition Partners with Delta Common to Sell PI Products Throughout India
This new partnership offers an exciting opportunity for PI to introduce its clean and natural products to millions. - November 17, 2023 - Performance Inspired Nutrition
Novugen Pharma (USA) LLC Launches ANDA Approved Midodrine 2.5mg, 5mg & 10mg
Novugen Pharma (USA) LLC has launched Midodrine 2.5mg, 5mg and 10mg in the U.S. upon the approval from ANDA by FDA. Novugen’s Midodrine will be manufactured in Malaysia by Novugen Pharma Sdn. Bhd. Midodrine is indicated for the treatment of symptomatic orthostatic hypotension, a condition defined as a sudden drop in blood pressure upon standing from a sitting or supine position. - November 07, 2023 - Novugen
Microvascular Therapeutics Receives $3.98M Award from Department of Defense for Its Cardiovascular Product
Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, AZ, was recently awarded a $3.98M FY22 Technology/Therapeutic Development – Funding Level 2 grant from the Congressionally Directed Medical Research Programs (CDMRP). Emmanuelle Meuillet, Chief... - October 18, 2023 - Microvascular Therapeutics, Inc.
Huntington Study Group® Observational Pilot Study Shows HSG’s myHDstory® Platform Reaches the Unreachable
The Huntington Study Group® (HSG) together with its wholly owned subsidiary, HSG Clinical Research, Inc. (HSGCR), a world leader in conducting clinical trials for Huntington’s disease (HD), today announces that the pilot observational study on their innovative online direct-to-patient... - October 16, 2023 - Huntington Study Group
knowRX Strengthens Platform to Support Physician Engagement in Clinical Trial Diversity
knowRX, a clinical trial solutions provider, has launched an Investigator/Provider Learning Center on its PIXS™ platform, focusing on "Cultural Considerations in the Conduct of Clinical Trials." This initiative aims to educate physicians, increasing their awareness and understanding of clinical trials. The goal is to bridge gaps in patient access and awareness, particularly among underrepresented populations, aligning with recent FDA guidelines emphasizing diversity in clinical trials. - October 07, 2023 - knowRX, Inc.
Cayman Chemical Introduces a New Tool to Study Protein-Lipid Interactions
Cayman LipiDOT Strips™ are a simple tool for the rapid identification of protein-lipid interactions. Researchers can screen a protein of interest against 22 biologically relevant lipids in one assay in a single day at a lower price compared with existing commercial options. - October 04, 2023 - Cayman Chemical Company
GeneProof Announces Expansion of Its IVDR-Certified PCR Portfolio
GeneProof, a leader in molecular diagnostics, today announced the addition of six new IVDR-certified PCR kits to its expansive portfolio. This comes as a testament to the company’s dedication to delivering its entire portfolio of approximately 80 products as IVDR compliant by 2027. Currently,... - October 03, 2023 - ALPCO
Gotham Biotech's New Histoplasma Urinary Antigen EIA Kit Now Available for Purchase
The Gotham Biotech Histoplasma Urinary Antigen EIA is an enzyme immunoassay (EIA) intended to qualitatively detect the presence of Histoplasma capsulatum galactomannan antigen in human urine specimens. This kit, when used in conjunction with other diagnostic measures, can be used as an aid in the diagnosis of histoplasmosis. - September 08, 2023 - Gotham Biotech
Huntington Study Group Welcomes FDA Approval of New Drug for Chorea in Huntington’s Disease
The Huntington Study Group (HSG) together with its wholly owned subsidiary, HSG Clinical Research, Inc., a world leader in clinical trials for Huntington’s disease (HD), today shares that the Phase 3 pivotal KINECT®-HD study conducted by HSG in collaboration with Neurocrine Biosciences,... - August 18, 2023 - Huntington Study Group
Huntington Study Group Announces Positive Topline Results for Virtual Unified Huntington’s Disease Rating Scale® (vUHDRS®) Study
The Huntington Study Group (HSG) together with its wholly owned subsidiary, HSG Clinical Research, Inc., a world leader in conducting clinical trials for Huntington’s disease (HD), today announces positive topline results from its Virtual Unified Huntington’s Disease Rating Scale®... - August 14, 2023 - Huntington Study Group
Minus K Technology Announces Announces Its Eighth U.S. Educational Giveaway of Vibration Isolators to Colleges and Universities
Minus K Technology, over the past 30 years has worked with businesses, universities and laboratories all over the world, supplying negative-stiffness vibration isolation products for research within universities, aerospace, audio reproduction, crystal growth, neuroscience, biology, chemistry,... - August 09, 2023 - Minus K Technology Inc.
VitaliNatura Essentials™ Launches Exclusive Product Line for Women in Mid-Life and Beyond
VitaliNatura Essentials™, a 100% women-owned company, proudly launches an exclusive product line for women in mid-life and beyond. The collection includes premium vitamins and supplements tailored to cater to the unique needs of women in their mid-40s and after. The company's commitment to quality and empowerment shines through as they offer Adrenal Support Supplements, Magnesium Gummies, Sea Moss Gummies, Liver Support Capsules, Berberine Complex, Joint Health Capsules, and more. - August 01, 2023 - VitaliNatura Essentials DBA EngagePro Digital, LLC
Huntington Study Group and CHDI Foundation Collaborate on Enroll-HD
HSG Clinical Research, Inc. - the Huntington Study Group’s clinical research organization (CRO) and wholly owned subsidiary (collectively referred to here as HSG) - has begun providing CRO services for CHDI Foundation’s Enroll-HD observational study and clinical research platform in the... - July 25, 2023 - Huntington Study Group
Cayman and Navinci Announce Strategic Partnership, Expanding Access to Next-Generation Tools for Spatial Proteomics
Cayman and Navinci have partnered to bring next-generation proximity ligation-based solutions for spatial proteomics to US and Canada-based researchers. - July 13, 2023 - Cayman Chemical Company
Paras Biopharma (Biologics CDMO) Announces Industry Leading Scale-up Development & Production Process of an “Onco-Immunology Fc-fusion Biologic”
Paras Biopharma (Biologics CDMO) Finland team is pleased to announce that its extensive efforts have resulted in the successful scale-up, optimization & development of a biologically-active onco-immunology, “peptide FC-fusion” biologic. - July 12, 2023 - Paras Biopharmaceuticals Finland Oy
Paras Biopharma (Biologics CDMO) Maximises Recombinant Protein Expression in Microbial Systems – To Facilitate Economical Scale-Up in Production of Biologics
Paras Biopharma (Biologics CDMO) Finland, a leading biopharmaceutical technology development company in the Nordic region, maximises recombinant protein expression in Microbial Systems in its fully-equipped biologics production facility in Finland. - July 04, 2023 - Paras Biopharmaceuticals Finland Oy
Tialma's Aleksey Krylov Attending NewYorkBIO Life Science Company Showcase
Tialma, a CFO consultancy to the life science companies, is sharing that its lead consultant Aleksey Krylov will attend the highly anticipated NewYorkBIO Life Science Company Showcase, scheduled to take place on June 27, 2023. The NewYorkBIO Life Science Company Showcase is an esteemed event that... - June 27, 2023 - Tialma
Aleksey Krylov Joining Oncology Advanced Practice Forum Online Conference
Tialma, a CFO consultancy to the life science companies, is sharing that its lead consultant Aleksey Krylov will join Oncology Advanced Practice Forum Online Conference, scheduled to take place on June 26, 2023. Tialma chose this event because of its versatility, which enables networking... - June 26, 2023 - Tialma
Alventa Pharma Pvt. Ltd. Introduces Affordable Generic Pharmaceutical Drugs and Extends Contract Manufacturing Services
India-based Alventa Pharma, a leading third party manufacturing pharma, is excited to announce the launch of their cost-effective generic drugs in both domestic and international markets. Alongside being Third party manufacturing pharma, Alventa Pharma now expands its services as a contract... - June 21, 2023 - Alventa Pharma Limited
PharmStars Announces Spring 2023 Accelerator Graduates: 13 Digital Health Startups Complete PharmStars’ Pharma-Focused Accelerator Program
PharmStars, the pharma-focused accelerator for digital health startups, announces that 13 startups have graduated from its Spring 2023 program focused on “Innovations in Women’s Health or Health Equity.” The graduating startups successfully completed PharmaU, PharmStars’ 10-week program. PharmaU culminated with a Showcase Event, held in Boston in May, that brought together the participating startups and PharmStars’ innovation-minded pharma members. - June 20, 2023 - PharmStars
ALPCO Receives FDA 510(k) Clearance for the Calprotectin Immunoturbidimetric Assay
American Laboratory Products Company, Ltd. ("ALPCO"), a global provider of specialty diagnostic solutions, today announced recent FDA 510(k) clearance of its Calprotectin Immunoturbidimetric Assay. The Calprotectin Immunoturbidimetric (IT) Assay is now IVDD and 510(k)-cleared for in... - June 15, 2023 - ALPCO
PharmStars Announces “Digital Innovations in Therapeutic Delivery: Supply Chain to the Patient Interface” Theme for its Fall 2023 Accelerator
PharmStars, the pharma-focused accelerator for digital health startups, is accepting applications for its Fall 2023 cohort around the theme “Digital Innovations in Therapeutic Delivery: Supply Chain to the Patient Interface.” The cohort is open to startups with digital health solutions that pharma can use to innovate therapeutic supply chain management, medication delivery, or the patient-drug experience for small molecules, biologics, or advanced therapies. Applications are due July 10, 2023. - June 06, 2023 - PharmStars
GenInvo Part of PHUSE US Connect & Informa Connect Clinical Data Disclosure, Transparency & Plain Language Summaries Event - 2023
GENINVO was a part of 2 recent global events for the life science industry. The first was "PHUSE US Connect 2023" which was held in Renaissance Orlando at SeaWorld Florida on 5th – 8th March 2023 and the second event, Informa Connect Clinical Data Disclosure, Transparency &... - June 05, 2023 - GenInvo, Inc.
Opening New Frontiers in Oral Care and the Cannabinoid Market
A groundbreaking patent has been unveiled, presenting a revolutionary method for the prevention and treatment of dental pulp-associated diseases using a cannabinoid-based composition. This patent offers pharmaceutical companies a unique opportunity to enter the rapidly growing cannabinoid market while addressing critical dental care needs. - June 04, 2023 - CannIBite
New Research Benchmarks Biopharmaceutical Perceptions of Global CRO Thought Leadership
Landmark Research Analyzes Perspectives of US and EU Biopharma C-Suite, Clinical Operations and Medical/Regulatory Affairs Professionals on Global CRO Thought Leadership. - June 01, 2023 - Life Science Strategy Group, LLC
Huntington Study Group Announces Call for Abstracts for 30th Annual Meeting
The Huntington Study Group (HSG), with a mission of accelerating treatments that make a difference for those impacted by Huntington’s disease, together with its wholly owned subsidiary, HSG Clinical Research, Inc., a world leader in conducting clinical trials for Huntington’s disease... - June 01, 2023 - Huntington Study Group
OPTI•MIST® Introduces Innovative Organic Personal Care Products
OPTI•MIST® Organic Introduces Innovative Organic Personal Care Products Infused with a Powerful Mineral-Based Antiseptic for Enhanced Hygiene. OPTI•MIST, a pioneering brand in the personal care industry, is pleased to announce the launch of its revolutionary line of organic personal... - May 26, 2023 - OPTI-LAB INC.
The Inc. Magazine, USA Includes Paras Biopharma (Biologics CDMO) as One of the Top 10 Most Innovative Biotech Companies to Follow in 2023
Paras Biopharma (Biologics CDMO), a biopharmaceutical technology development company is pleased to be included by The Inc. Magazine, USA as “One of the Top 10 Most Innovative Biotech Companies to Follow in 2023.” The Inc. Magazine serves as an online "go-to" informative tool for business leaders and entrepreneurs, including CEOs and owners of small-to-midsize companies to success, providing news, advice, and inspirational articles. - May 19, 2023 - Paras Biopharmaceuticals Finland Oy
Neurocrine Biosciences Announces Publication of Full KINECT™-HD Phase 3 Study Results of Valbenazine
Neurocrine Biosciences Announces Publication of Full KINECT™-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington’s Disease in The Lancet Neurology. - Statistically Significant Improvement in Chorea Associated with Huntington’s Disease... - May 19, 2023 - Huntington Study Group
PharmStars Announces Spring 2023 Startup Showcase Event Underway
PharmStars, the pharma-focused accelerator for digital health startups, announces that its fourth Showcase Event begins May 16, 2023. The Showcase is the culmination of the Spring 2023 10-week accelerator program. At the Showcase, each startup in the fourth cohort makes a formal presentation to and meets individually with PharmStars’ pharma members. The theme of the Spring 2023 program is digital innovations in women’s health or health equity. - May 16, 2023 - PharmStars
Huntington Study Group Achieves Last Patient Last Visit for Its Observational Study to Test Virtual Use of the Unified Huntington’s Disease Rating Scale®
The Huntington Study Group (HSG) together with its wholly owned subsidiary, HSG Clinical Research, Inc., announces an important milestone in the novel observational study Virtual Unified Huntington’s Disease Rating Scale (vUHDRS™). The last participant completed the last visit, marking... - May 16, 2023 - Huntington Study Group